Mobile health interventions in multiple sclerosis: A systematic review.
Mobile health
digitalization
patient-reported outcomes
randomized controlled trials
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
30
11
2023
pubmed:
29
10
2023
entrez:
28
10
2023
Statut:
ppublish
Résumé
Persons with multiple sclerosis (pwMS) might be particularly well suited to benefit from digital health applications because they are, on average, younger and less severely disabled than patients with many other chronic diseases. Many digital health applications for pwMS have been developed. Analysis of the evidence of digital health applications to improve health outcomes from a patient perspective. A systematic review was performed on all randomized controlled trials (RCTs) that have studied mobile health interventions for pwMS, that is, which can be applied with a smartphone, tablet, or laptop to improve patient-reported outcomes. Of the 1127 articles identified in the literature search, 13 RCTs fit the inclusion criteria. Two trials studied messaging systems, two depression interventions, one addressed MS fatigue, five cognition, and three mobility issues, of which two focused on spasticity management. One trial aimed to enhance physical activity. Most were pilot studies that cannot yield definitive conclusions regarding efficacy. One depression intervention and one fatigue intervention showed significant results across several outcomes. Several mobile self-guided digital health applications for pwMS have been tested in RCTs, and two interventions targeting depression and fatigue have demonstrated significant effects. Challenges remain regarding implementation into routine care.
Sections du résumé
BACKGROUND
UNASSIGNED
Persons with multiple sclerosis (pwMS) might be particularly well suited to benefit from digital health applications because they are, on average, younger and less severely disabled than patients with many other chronic diseases. Many digital health applications for pwMS have been developed.
OBJECTIVES
UNASSIGNED
Analysis of the evidence of digital health applications to improve health outcomes from a patient perspective.
METHODS
UNASSIGNED
A systematic review was performed on all randomized controlled trials (RCTs) that have studied mobile health interventions for pwMS, that is, which can be applied with a smartphone, tablet, or laptop to improve patient-reported outcomes.
RESULTS
UNASSIGNED
Of the 1127 articles identified in the literature search, 13 RCTs fit the inclusion criteria. Two trials studied messaging systems, two depression interventions, one addressed MS fatigue, five cognition, and three mobility issues, of which two focused on spasticity management. One trial aimed to enhance physical activity. Most were pilot studies that cannot yield definitive conclusions regarding efficacy. One depression intervention and one fatigue intervention showed significant results across several outcomes.
CONCLUSION
UNASSIGNED
Several mobile self-guided digital health applications for pwMS have been tested in RCTs, and two interventions targeting depression and fatigue have demonstrated significant effects. Challenges remain regarding implementation into routine care.
Identifiants
pubmed: 37897326
doi: 10.1177/13524585231201089
pmc: PMC10687804
doi:
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1709-1720Déclaration de conflit d'intérêts
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: B.M. is employed as the Research Director by GAIA, the company that has developed, owns, and operates deprexis, amiria, and elevida. C.H. and J.P. also contributed to the trials of these applications. K.R.-L. and N.K. are involved in another digital health intervention development with GAIA. T.B. and D.L. declare no conflicts of interest. T.F. has no conflicts of interest. C.H. received research support from Bristol Myers Squibb, Novartis, and Merck. He received honoraria from Roche for digital health presentations.
Références
J Med Internet Res. 2013 Mar 17;15(4):e67
pubmed: 23635393
Mult Scler. 2009 Dec;15(12):1509-17
pubmed: 19995840
PeerJ. 2020 Jun 23;8:e9303
pubmed: 32612882
Eur J Neurol. 2022 Jun;29(6):1697-1707
pubmed: 35122365
Mult Scler. 2021 Apr;27(5):778-789
pubmed: 32584155
PLoS One. 2017 May 11;12(5):e0177177
pubmed: 28493924
Brain Sci. 2021 Aug 19;11(8):
pubmed: 34439706
Brain Sci. 2021 Nov 16;11(11):
pubmed: 34827518
Trials. 2011 Dec 14;12:259
pubmed: 22168507
Clin Ther. 2008 May;30(5):974-85
pubmed: 18555944
Neuropsychol Rehabil. 2020 Jan;30(1):15-31
pubmed: 29557731
Psychiatry Res. 2017 Oct;256:371-377
pubmed: 28686935
Lancet Psychiatry. 2015 Mar;2(3):217-23
pubmed: 26359900
BMC Med Inform Decis Mak. 2021 Jan 21;21(1):24
pubmed: 33478502
Internet Interv. 2017 Jun 02;9:46-50
pubmed: 30135836
Neural Plast. 2016;2016:4292585
pubmed: 28116167
J Psychosom Res. 2010 Jul;69(1):17-22
pubmed: 20630259
Mult Scler. 2013 Aug;19(9):1240-1
pubmed: 23388164
Mult Scler Relat Disord. 2017 Oct;17:15-21
pubmed: 29055449
J Telemed Telecare. 2020 Aug-Sep;26(7-8):400-413
pubmed: 31042118
Telemed J E Health. 2011 Jan-Feb;17(1):5-13
pubmed: 21214498
J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):970-976
pubmed: 29549193
J Clin Epidemiol. 2019 Jun;110:74-81
pubmed: 30826377
J Med Internet Res. 2011 Dec 31;13(4):e126
pubmed: 22209829
Neurorehabil Neural Repair. 2015 Jun;29(5):453-61
pubmed: 25398725
JMIR Rehabil Assist Technol. 2018 Apr 24;5(1):e5
pubmed: 29691208
JMIR Form Res. 2018 Dec 12;2(2):e11977
pubmed: 30684408
Mult Scler. 2018 Nov;24(13):1657-1664
pubmed: 30231004
Mult Scler J Exp Transl Clin. 2015 Oct 05;1:2055217315609629
pubmed: 28607707